Abstract
Atherosclerotic coronary heart disease (CHD) is a major health problem worldwide. Epidemiological studies have identified the role of several modifiable and non-modifiable risk factors in the pathogenesis of CHD. Aggressive risk modification has led to a significant improvement in the morbidity and mortality from CHD. However, there is a growing need to identify better modalities of risk prediction in CHD. Many of these newer risk markers, currently under evaluation, are based on the newer concept that atherosclerosis is more than merely a problem of lipid imbalance. There has been a recent shift in the paradigm towards inflammation and oxidative stress as the key drivers in the pathophysiology of atherosclerosis and its complications. Further understanding of this complex interplay of lipid and inflammatory factors is likely to pave way to a better understanding of this disease and its myriad complications.
Keywords: Atherosclerosis, Coronary Heart Disease, Atherosclerotic coronary heart disease (CHD), lipoprotein, menopause, Hypercholesterolemia, atheroma growth, triglycerides, cardiovascular disease, dyslipidemia, hyperglycemia, atheroma, fibroatheroma, hemorrhage, thrombosis, Positron emission tomography (PET), neovascularization, photodynamic therapy (PDT)
Cardiovascular & Hematological Disorders-Drug Targets
Title: Atherosclerotic Coronary Heart Disease Epidemiology, Classification and Management
Volume: 10 Issue: 4
Author(s): Smita Negi and Aashish Anand
Affiliation:
Keywords: Atherosclerosis, Coronary Heart Disease, Atherosclerotic coronary heart disease (CHD), lipoprotein, menopause, Hypercholesterolemia, atheroma growth, triglycerides, cardiovascular disease, dyslipidemia, hyperglycemia, atheroma, fibroatheroma, hemorrhage, thrombosis, Positron emission tomography (PET), neovascularization, photodynamic therapy (PDT)
Abstract: Atherosclerotic coronary heart disease (CHD) is a major health problem worldwide. Epidemiological studies have identified the role of several modifiable and non-modifiable risk factors in the pathogenesis of CHD. Aggressive risk modification has led to a significant improvement in the morbidity and mortality from CHD. However, there is a growing need to identify better modalities of risk prediction in CHD. Many of these newer risk markers, currently under evaluation, are based on the newer concept that atherosclerosis is more than merely a problem of lipid imbalance. There has been a recent shift in the paradigm towards inflammation and oxidative stress as the key drivers in the pathophysiology of atherosclerosis and its complications. Further understanding of this complex interplay of lipid and inflammatory factors is likely to pave way to a better understanding of this disease and its myriad complications.
Export Options
About this article
Cite this article as:
Negi Smita and Anand Aashish, Atherosclerotic Coronary Heart Disease Epidemiology, Classification and Management, Cardiovascular & Hematological Disorders-Drug Targets 2010; 10 (4) . https://dx.doi.org/10.2174/187152910793743832
DOI https://dx.doi.org/10.2174/187152910793743832 |
Print ISSN 1871-529X |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-4063 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Incretin-Based Antidiabetic Agents for the Management of Non-Alcoholic Fatty Liver Disease
Current Vascular Pharmacology Ginkgo biloba Extract in Vascular Protection: Molecular Mechanisms and Clinical Applications
Current Vascular Pharmacology Current Nanotechnological Approaches for an Effective Delivery of Bioactive Drug Molecules to Overcome Drug Resistance Tuberculosis
Current Pharmaceutical Design Immune Response Towards Snake Venoms
Inflammation & Allergy - Drug Targets (Discontinued) Military Risk Factors for Cognitive Decline, Dementia and Alzheimer’s Disease
Current Alzheimer Research The Application of Rational Design on Phospholipase A2 Inhibitors
Current Medicinal Chemistry Myxedema Heart Disease: A Rare Disease Entity: Case Report and Brief Review of the Literature
Current Hypertension Reviews Potential Role of Inflammation in Associations between Particulate Matter and Heart Failure
Current Pharmaceutical Design Scorpion Toxin Polyptides as Therapeutic Agents: An Overview
Protein & Peptide Letters Are Cerebrovascular White Matter Lesions an Early Sign of Vascular Cognitive Impairment and Vascular Dementia?
Vascular Disease Prevention (Discontinued) Emerging Indications for Statins: A Pluripotent Family of Agents with Several Potential Applications
Current Pharmaceutical Design Excess Exposure to Insulin Is the Primary Cause of Insulin Resistance and its Associated Atherosclerosis
Current Molecular Pharmacology Infection-Associated Biomarkers of Inflammation in Atherosclerosis
Current Pharmaceutical Design Antivitamin K Drugs in Stroke Prevention
Current Vascular Pharmacology Editorial: Do Some Glucagon-Like-Peptide-1 Receptor Agonists (GLP-1 RA) Reduce Macrovascular Complications of Type 2 Diabetes Mellitus? (A Commentary on the Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) Trial)
Current Vascular Pharmacology Older Adults Prescribed Methadone: A Review of the Literature Across the Life Span from Opiate Initiation to Methadone Maintenance Treatment
Current Drug Abuse Reviews Modulation of Ion Channels in Pulmonary Arterial Hypertension
Current Pharmaceutical Design Pharmacotherapy of Mixed Dyslipidemia in the Metabolic Syndrome
Current Clinical Pharmacology Factor VIII Levels are Associated with Ischemic Stroke, Stroke Subtypes and Neurological Worsening
Current Neurovascular Research Development of Monoclonal Antibody Against Chlorinated 192tyrosine Containing ApoAI Peptide to Screen Quality of Human High Density Lipoprotein (HDL)
Protein & Peptide Letters